Teduglutide
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Teduglutide?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Teduglutide, sold under the brand names Revestive (EU) and Gattex (US), is a 33-membered polypeptide and glucagon-like peptide-2 (GLP-2) analog that is used for the treatment of short bowel syndrome. It works by promoting mucosal growth and possibly restoring gastric emptying and secretion.[7] It was approved in both the European Union[5] and the United States in 2012.[4]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Revestive, Gattex |
AHFS/Drugs.com | Monograph |
License data |
|
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 88% |
Metabolism | Proteolysis |
Elimination half-life | 2h |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII | |
KEGG |
|
ChEBI | |
Chemical and physical data | |
Formula | C164H252N44O55S |
Molar mass | 3752.13 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Close